Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

The Arizona Board of Pharmacy last week moved to delay enforcement of new USP 795, 797, and 800 chapters in the state.

At the request of the Arizona Pharmacists Association and other groups, the board vacated its June 2023 vote to adopt and enforce the new chapters starting November 1, and instead voted to convene a task force to review the new guidelines to determine whether they will be enforced at all, enforced in part, or enforced based on pharmacy service acuity/risk analysis.

The Scottsdale-based law firm Boesen & Snow represented the above-named clients in this matter and made persuasive arguments to the board.

This is a prudent step by the board, and we believe the June advisory memo we sent to state boards of pharmacy helped ensure the messaging was clear.